Physician profile
Rogers Smith Walker
NPI 1285725408
$2,169.17
in general payments reported to CMS, 2019-2025
30 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $276 · 2021: $225 · 2022: $229 · 2023: $382 · 2024: $472 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $299.48 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $245.88 | 2020-2025 | Farxiga, Airsupra |
| Abbvie INC. | $220.44 | 2019-2025 | Vraylar |
| Novo Nordisk INC | $156.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $135.50 | 2019-2025 | Veozah |
| Amgen INC. | $128.59 | 2019-2024 | Otezla, Repatha, Krystexxa |
| Exact Sciences Corporation | $91.78 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $91.34 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $91.05 | 2020 | |
| Pfizer INC. | $79.50 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $73.65 | 2025 | Rexulti |
| Dexcom, INC. | $67.88 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $55.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.39 | 2021 | |
| Xeris Pharmaceuticals, INC. | $45.62 | 2023-2025 | Gvoke Hypopen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.39 | 2024 | Voquezna |
| Boston Scientific Corporation | $29.23 | 2024 | Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $28.21 | 2023-2024 | Quviviq |
| Averitas Pharma INC. | $28.02 | 2024 | Qutenza |
| Kvk-Tech, INC. | $26.82 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.87 | 2024 | Caplyta |
| Corcept Therapeutics | $23.50 | 2025 | Korlym |
| Nevro Corp. | $20.26 | 2024 | Senza |
| Hologic Sales and Service, LLC | $19.50 | 2023 | Aptima, Thinprep 2000 Processor |
| Biohaven Pharmaceuticals, INC. | $18.47 | 2021 | |
| Tolmar, INC. | $18.25 | 2025 | Jatenzo |
| Axsome Therapeutics, INC. | $18.19 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $17.47 | 2023 | Eliquis |
| Genentech USA, INC. | $17.32 | 2021 | |
| Forte Bio-Pharma LLC | $10.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rogers Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.